These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 27589846)

  • 1. Application of pharmacologically induced transcriptomic profiles to interrogate PI3K-Akt-mTOR pathway activity associated with cancer patient prognosis.
    Ung MH; Wang GL; Varn FS; Cheng C
    Oncotarget; 2016 Dec; 7(51):84142-84154. PubMed ID: 27589846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
    Chen X; Zhao M; Hao M; Sun X; Wang J; Mao Y; Zu L; Liu J; Shen Y; Wang J; Shen K
    Mol Cancer Res; 2013 Oct; 11(10):1269-78. PubMed ID: 23814023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of PI3K-Akt-mTOR signal pathway dismissed the stimulation of glucose on goose liver cell growth.
    Wei S; Han C; He F; Song Q; Kang B; Liu H; Li L; Xu H; Zeng X
    J Anim Physiol Anim Nutr (Berl); 2017 Oct; 101(5):e133-e143. PubMed ID: 27859698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of the cell cycle and PI3K/Akt/mTOR signaling pathway by tanshinone I in human breast cancer cell lines.
    Wang L; Wu J; Lu J; Ma R; Sun D; Tang J
    Mol Med Rep; 2015 Feb; 11(2):931-9. PubMed ID: 25355053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carnosine inhibits glioblastoma growth independent from PI3K/Akt/mTOR signaling.
    Oppermann H; Faust H; Yamanishi U; Meixensberger J; Gaunitz F
    PLoS One; 2019; 14(6):e0218972. PubMed ID: 31247000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway.
    DeGraffenried LA; Fulcher L; Friedrichs WE; Grünwald V; Ray RB; Hidalgo M
    Ann Oncol; 2004 Oct; 15(10):1510-6. PubMed ID: 15367412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of endoplasmic reticulum stress on the autophagy, apoptosis, and chemotherapy resistance of human breast cancer cells by regulating the PI3K/AKT/mTOR signaling pathway.
    Zhong JT; Yu J; Wang HJ; Shi Y; Zhao TS; He BX; Qiao B; Feng ZW
    Tumour Biol; 2017 May; 39(5):1010428317697562. PubMed ID: 28459209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of PI3K/Akt/mTOR signaling in the tumor stroma drives endocrine therapy-dependent breast tumor regression.
    Polo ML; Riggio M; May M; Rodríguez MJ; Perrone MC; Stallings-Mann M; Kaen D; Frost M; Goetz M; Boughey J; Lanari C; Radisky D; Novaro V
    Oncotarget; 2015 Sep; 6(26):22081-97. PubMed ID: 26098779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deciphering downstream gene targets of PI3K/mTOR/p70S6K pathway in breast cancer.
    Heinonen H; Nieminen A; Saarela M; Kallioniemi A; Klefström J; Hautaniemi S; Monni O
    BMC Genomics; 2008 Jul; 9():348. PubMed ID: 18652687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IGFBP-2 expression in MCF-7 cells is regulated by the PI3K/AKT/mTOR pathway through Sp1-induced increase in transcription.
    Mireuta M; Darnel A; Pollak M
    Growth Factors; 2010 Aug; 28(4):243-55. PubMed ID: 20370577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extract from Astragalus membranaceus inhibit breast cancer cells proliferation via PI3K/AKT/mTOR signaling pathway.
    Zhou R; Chen H; Chen J; Chen X; Wen Y; Xu L
    BMC Complement Altern Med; 2018 Mar; 18(1):83. PubMed ID: 29523109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-associated macrophages secrete CC-chemokine ligand 2 and induce tamoxifen resistance by activating PI3K/Akt/mTOR in breast cancer.
    Li D; Ji H; Niu X; Yin L; Wang Y; Gu Y; Wang J; Zhou X; Zhang H; Zhang Q
    Cancer Sci; 2020 Jan; 111(1):47-58. PubMed ID: 31710162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The antitumor effect of GDC-0941 alone and in combination with rapamycin in breast cancer cells.
    Zheng J; Zou X; Yao J
    Chemotherapy; 2012; 58(4):273-81. PubMed ID: 23006739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
    deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
    Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
    Vega F; Medeiros LJ; Leventaki V; Atwell C; Cho-Vega JH; Tian L; Claret FX; Rassidakis GZ
    Cancer Res; 2006 Jul; 66(13):6589-97. PubMed ID: 16818631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LY294002 and Rapamycin promote coxsackievirus-induced cytopathic effect and apoptosis via inhibition of PI3K/AKT/mTOR signaling pathway.
    Chen Z; Yang L; Liu Y; Tang A; Li X; Zhang J; Yang Z
    Mol Cell Biochem; 2014 Jan; 385(1-2):169-77. PubMed ID: 24072614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benzo[b]furan derivatives induces apoptosis by targeting the PI3K/Akt/mTOR signaling pathway in human breast cancer cells.
    Kamal A; Lakshma Nayak V; Nagesh N; Vishnuvardhan MV; Subba Reddy NV
    Bioorg Chem; 2016 Jun; 66():124-31. PubMed ID: 27149364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simvastatin-induced breast cancer cell death and deactivation of PI3K/Akt and MAPK/ERK signalling are reversed by metabolic products of the mevalonate pathway.
    Wang T; Seah S; Loh X; Chan CW; Hartman M; Goh BC; Lee SC
    Oncotarget; 2016 Jan; 7(3):2532-44. PubMed ID: 26565813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. eIF4B is a convergent target and critical effector of oncogenic Pim and PI3K/Akt/mTOR signaling pathways in Abl transformants.
    Chen K; Yang J; Li J; Wang X; Chen Y; Huang S; Chen JL
    Oncotarget; 2016 Mar; 7(9):10073-89. PubMed ID: 26848623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells.
    Block M; Gründker C; Fister S; Kubin J; Wilkens L; Mueller MD; Hemmerlein B; Emons G; Günthert AR
    Int J Oncol; 2012 Nov; 41(5):1845-54. PubMed ID: 22922893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.